Advancements in ophthalmology at the European Society of Cataract and Refractive Surgeons

This year’s European Society of Cataract and Refractive Surgeons (ESCRS) congress was a great success for both its members and the greater ophthalmological community. The meeting kept teaching and training at the heart of the congress and boasted 16 symposia, 492 free papers, 1,257 posters, 125 courses and 64 wetlabs. Located in Lisbon, Portugal, more than 9,800 delegates from 120 countries were present resulting in record breaking attendance from 7 – 11 October, 2017.1

In keeping with the spirit of education, VISUfarma was eager to present a Lunch Symposium on Monday, 9th October titled “Coenzyme Q10: New approach in the treatment of corneal damage and glaucoma”. The Symposium was extremely well attended by professionals representing countries from across Europe and around the globe. A full report of the symposium intended for healthcare professionals can be accessed at www.VisuXL.com. However, a few key points are as follows:

• Dry eye disease is a condition comprised of many different factors which ultimately result in discomfort, visual disturbance, and tear film instability2
• Coenzyme Q10 (CoQ10) has two important functions. It is a key component for the generation of ATP in the mitochondria and it has anti-oxidant effects to neutralize reactive oxidant species (ROS)
• A new combination of cross-linked hyaluronic acid and Coenzyme Q10 is very useful in the treatment of dry eye induced ocular surface damage. It may also accelerate corneal recovery following trauma or surgery4
• There is currently an unmet need in glaucoma, successful intraocular pressure (IOP) reduction does not necessarily prevent loss of vision5,6,7
• Recent evidence indicates that there is a link between the progression of glaucoma and mitochondrial dysfunction8,9,10
• Coenzyme Q10 targets the mitochondria, appears to reach the back of the eye and suggests the potential utility of a neuroprotective therapy for the treatment of glaucoma11

The feedback from the Symposium exceeded our expectations and we look forward to continuing to educate medical professionals on the ophthalmic uses of Coenzyme Q10 as well as providing patients with new, innovative treatment options. The knowledge shared and connections made at the congress were further proof for us of the big changes coming in ophthalmology, and we look forward to playing a major role in the coming period.

References
1. Kerr C. ‘Record attendance at ESCRS congress’. Euro Times 2017 November 1; Retrieved December 22, 2017, from http://www.eurotimes.org/record-attendance-escrs-congress/
2. Nelson JD et al. TFOS DEWS II Introduction. Ocul Surf 2017 July;15(3):269-275.
3. Papucci L et al. Coenzyme Q10 prevents apoptosis by inhibiting the mitochondrial depolarization independently of its free radical scavenging property. J Biol Chem 2003;278(30):28220-28228.
4. Postorino et al. Efficacy of eyedrops containing cross-linked hyaluronic acid and coenzyme q10 in treating patients with mild to moderate dry eye. Eur J Ophthalmol 2017; DOI: 10.5301/ejo.6001011
5. Kass, MA et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002 June;120(6):714-20.
6. Heijl A et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002 Oct;120(10):1268-79.
7. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 119;126(4):487-97.
8. Lee D, et al. Coenzyme Q10 ameliorates oxidative stress and prevents mitochondrial alteration in ischemic retinal injury. Apoptosis 2014;19(4):603-14.
9. Park SW et al. A selective inhibitor of drp1, mdivi-1, increases retinal ganglion cell survival in acute ischemic mouse retina. Ophthalmol Vis Sci 2011 April;52(5):2837-43.
10. Ju WK, Lindsey JD, Angert M, Patel A, Weinreb RN. Glutamate receptor activation triggers OPA1 release and induces apoptotic cell death in ischemic rat retina. Mol Vis 2001 December;14:2629-2683.
11. Cordeiro MF, Guo L, Cheung W ,Wood N, Salt NE. Topical CoQ10 is Neuroprotective in Experimental

Choose country website



By clicking “Go” you are agreeing to leave the global VISUfarma website
and be directed to a regional website.